Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

You probably don’t need more time. By Jancee Dunn When I look back on all the major decisions I’ve dithered over, I could scream. It took me a decade to commit to becoming a parent. I wavered for a ...

Without using iteration and without using strings, write the recursive function onlyEvenDigits(L), that takes a list L of non-negative integers (you may assume that), and returns a new list of the ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

This is Part 4 in a 7-part series about world poker champion and cognitive scientist Annie Duke, Ph.D., whose insights follow each question below. To read from the start of the series, see Part 1.